¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"rapid streptococcal antigen test"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • granulocyte-monocyte antigen
    °ú¸³±¸´ÜÇÙ±¸Ç׿ø
  • granulocyte-specific antigen
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group antigen
    ¹«¸®Ç׿ø, ±ºÇ׿ø
  • group-specific antigen
    ¹«¸®Æ¯ÀÌÇ׿ø, ±ºÆ¯ÀÌÇ׿ø
  • hepatitis B core antigen
    BÇü°£¿°ÇÙ½ÉÇ׿ø
  • hepatitis B surface antigen
    BÇü°£¿°Ç¥¸éÇ׿ø
  • heterogenetic antigen
    ÀÌÁ¾Ä£È­Ç׿ø
  • heterophil antigen
    ÀÌÁ¾Ä£È­Ç׿ø
  • hidden antigen
    ¼ûÀºÇ׿ø
  • histocompatibility antigen
    Á¶Á÷ÀûÇÕ¼ºÇ׿ø
  • homologous antigen
    µ¿Á¾Ç׿ø
  • human histocompatibility antigen
    »ç¶÷Á¶Á÷ÀûÇÕ¼ºÇ׿ø
  • human leukocyte antigen
    »ç¶÷¹éÇ÷±¸Ç׿ø
  • human leukocyte antigen complex
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕü
  • human leukocyte antigen complex gene
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕüÀ¯ÀüÀÚ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • pulmonary function test
    Æó±â´É°Ë»ç
  • quantitative test
    Á¤·®°Ë»ç
  • reduction test
    ȯ¿ø½ÃÇè
  • renal function test
    ÄáÆÏ±â´É°Ë»ç, ½ÅÀå±â´É°Ë»ç
  • Rorschach test
    ·Î¸£»þÇϰ˻ç
  • Schilling test
    ½¯¸µ°Ë»ç
  • screening test
    ¼±º°°Ë»ç
  • secretin test
    ¼¼Å©·¹Æ¾°Ë»ç
  • sentence completion test
    ¹®Àå¿Ï¼º°Ë»ç
  • statistical test
    Åë°è°ËÁ¤
  • test tube
    ½ÃÇè°ü
  • thematic apperception test
    ÁÖÁ¦Åë°¢°Ë»ç
  • tilt test
    ±â¸³°æ»ç°Ë»ç
  • treadmill test
    Æ®·¹µå¹Ð°Ë»ç
  • triple test
    »ïÁß°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • granulocyte-monocyte antigen
    °ú¸³±¸´ÜÇÙ±¸Ç׿ø
  • granulocyte-specific antigen
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group antigen
    ±ºÇ׿ø
  • group-specific antigen
    ±ºÆ¯ÀÌÇ׿ø
  • hepatitis B core antigen
    ºñÇü°£¿°ÇÙ½ÉÇ׿ø
  • hepatitis B surface antigen
    ºñÇü°£¿°Ç¥¸éÇ׿ø
  • heterogenetic antigen
    (¢¡heterophil antigen) ÀÌÁ¾Ä£È­Ç׿ø
  • heterophil antigen
    ÀÌÁ¾Ä£È­Ç׿ø
  • hidden antigen
    ¼ûÀºÇ׿ø
  • histocompatibility antigen
    Á¶Á÷ÀûÇÕÇ׿ø
  • homologous antigen
    µ¿Á¾Ç׿ø
  • human histocompatibility antigen
    »ç¶÷Á¶Á÷ÀûÇÕÇ׿ø
  • human leukocyte antigen
    »ç¶÷¹éÇ÷±¸Ç׿ø
  • incomplete antigen
    ºÒ¿ÏÀüÇ׿ø
  • labeled antigen
    Ç¥ÁöÇ׿ø
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • EBV capsid antigen (VCA)
    EB¹ÙÀÌ·¯½º ĸ½ÃµåÇ׿ø
  • EBV membrane antigen
    EB¹ÙÀÌ·¯½º ¸·Ç׿ø
  • EBV membrane antigen (MA)
    EB¹ÙÀÌ·¯½º ¸·Ç׿ø
  • Forssman antigen
    Æ÷½º¸¸Ç׿ø
  • Fy antigen/antibody
    Fy Ç׿ø/Ç×ü
  • Gag => group specifiic antigen/core
    ±×·ì<±º>ƯÀ̼º Ç׿ø/ÄÚ¾î
  • Gag antigen in HIV infection
    HIV °¨¿°ÀÇ gag Ç׿ø
  • Gag antigen:
    gag Ç׿ø
  • H antigen
    H Ç׿ø
  • H antigen
    HÇ׿ø, Æí¸ðÇ׿ø
  • H-Y histocompatibility antigen
    H-Y Á¶Á÷ÀûÇÕ¼º Ç׿ø
  • HBc Ag => hepatitis B core antigen
    B Çü °£¿° c Ç׿ø
  • HBc antigen
    BÇü °£¿°¹ÙÀÌ·¯½º ÇÙ½ÉÇ׿ø
  • HBe Ag => hepatitis B e antigen
    B Çü °£¿° e Ç׿ø
  • HBe antigen
    BÇü °£¿°¹ÙÀÌ·¯½º eÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • venereal disease research laboratory test =VDRL test
    ¼ºº´¿¬±¸¼Ò½ÄÅ×½ºÆ®.
  • a antigen
    A Ç׿ø
  • accessible antigen
    Á¢±Ù°¡´ÉÇ׿ø, ±ÙÁ¢Ç׿ø(ÐÎïÈù÷ê«).
  • analysis, antigen
    Ç׿øºÐ¼®
  • anti-extractable nuclear antigen
    Ç×-ÃßÃ⼺ ÇÙÇ׿ø
  • antigen
    Ç׿ø(ù÷ê«)
  • antigen
    Ç׿ø(ù÷ê«)
  • antigen
    Ç׿ø
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen binding capacity
    Ç׿ø°áÇÕ´É(¡­Ì¿ùêÒö).
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Vi antigen
    Vi Ç׿ø (ù÷ê«)
  • virus antigen
    ¹ÙÀÌ·¯½º Ç׿ø (ù÷ê«)
  • acrolein test
    ¾ÆÅ©·Ñ·¹ÀνÃÇè (ãËúÐ)
  • acute test
    ´Ü·® µ¶¼º½ÃÇè (Ó¤ÕáÔ¸àõãËúÐ)
  • adrenaline tolerance test
    ¾Æµå·¹³¯¸° ºÎÇϽÃÇè(ݶùÃãËúÐ)
  • albustix test
    ¾ËºÎ½ºÆ½½º½ÃÇè(ãËúÐ)
  • Ames test
    ¿¡ÀÓÁî °Ë»ç¹ý
  • antiglobulin consumption test
    Ç×(ù÷)±Û·ÎºÒ¸° ¼Ò¸ð½ÃÇè(á¼ÙÄãËúÐ)
  • antiglobulin test
    Ç×(ù÷)±Û·ÎºÒ¸° ½ÃÇè(ù÷ô÷ãËúÐ)
  • Aschheim-Zondek test
    ¾Æ»þÀÓ-Á¸µ¦ ½ÃÇè(ãËúÐ)
  • Ascoli test
    ¾Æ½ºÄݸ® ½ÃÇè(ãËúÐ)
  • Barfoed's test
    ¹Ù¸£ÆÐµå ½ÃÇè(ãËúÐ)
  • benzidine test
    º¥Áöµò½ÃÇè(ãËúÐ)
  • blind test
    ¸Í°Ë(ØîËþ)
  • Bradshaw test
    ºê·¡µå¼î¿ì ½ÃÇè(ãËúÐ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
DAT delayed-action tablet; dementia Alzheimer's type; dental aptitude test; diacetylthiamine; diet as to...
IT immunological test; immunotherapy; implantation test; individual therapy; information technology; in...
LFT latex fixation test; latex flocculation test; left fronto-transverse [fetal position]; liver functio...
LTT lactose tolerance test; leucine tolerance test; limited treadmill test; lymphocyte transformation te...
SAT saliva alcohol test; satellite; serum antitrypsin; single-agent chemotherapy; slide agglutination te...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
NREMS Non-rapid eye movement sleep
non-REMS Non-rapid eye movement sleep
RARE Rapid Acquisition Relaxation Enhanced
RARE Rapid Acquisition with Relaxation Enhancement
REALM Rapid Estimate Of Adult Literacy in Medicine
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • virus-specific surface antigen
    ¹ÙÀÌ·¯½º ƯÀ̼º Ç¥¸é Ç׿ø ¹ÙÀÌ·¯½º
  • zone of antigen excess
    Ç׿ø °úÀ×´ë
    ºñ±³Àû °í³óµµÀÇ Ç׿ø´ë·Î¼­ ħ°­¹ÝÀÀ¿¡¼­ °¡¿ë¼º º¹ÇÕü°¡ Çü¼ºµÇ¸ç ¹ÝÀÀÀÌ ¾ïÁ¦µÈ´Ù.
  • abrasion test
    ¸¶¸ê ½ÃÇè
    ¸¶¸ð¿¡ °ßµð´Â Á¤µµ¸¦ ½ÃÇèÇÏ´Â °Ë»ç.
  • acetest tablet test
    ¾Æ¼¼Å×½ºÆ® Á¤ ½ÃÇè
    ¹éÁö À§¿¡ ¿Ã·Á³õÀº ¾Æ¼¼Å×½ºÆ® Á¤¿¡ ¿ä ÇÑ ¹æ¿ïÀ» ¶³¾î¶ß¸± ¶§, ¾î´À Á¤µµÀÇ ¾Æ¼¼ÅæÀÌ Á¸ÀçÇÏ¸é ±× ¾ç¿¡ µû¶ó¼­ ¾Æ¼¼Å×½ºÆ® Á¤ÀÌ ´ãÀÚ»ö
  • acetoacetic acid test
    ¾Æ¼¼Åä ÃÊ»ê ½ÃÇè
  • achievement test
    ¼öµæ´É·Â °Ë»ç, ¼öµæ´É·Âµµ °Ë»ç
  • acid elution test
    »ê ¿ë¸® ½ÃÇè
    ÅÂ¾Æ Çì¸ð±Û·ÎºóÀÇ °ËÃâ ½ÃÇèÀ¸·Î, ½½¶óÀÌµå ±Û¶ó½º À§¿¡ °ø±â °ÇÁ¶µÈ Ç÷¾× µµÆ÷ Ç¥º»À» 80% ¸ÞŸ³î·Î °íÁ¤ÇÏ¿©,
  • acoustic reflex test
    û°¢¹Ý»ç ½ÃÇè
    û°¢¹Ý»ç ¿ªÄ¡ÀÇ ÃøÁ¤¹ýÀ¸·Î¼­ Àüµµ¼º°ú °¨°¢½Å°æ¼º ³­Ã»À» °¨º° Áø´ÜÇϰųª û½Å°æÁ¾À» Áø´ÜÇÏ´Â µ¥ ÀÌ¿ëµÈ´Ù.
  • ACTH stimulation test
    ACTH ÀÚ±Ø °Ë»ç
    Çϼöü ºÎ½ÅÇÇÁú°è ¿¹ºñ·Â°Ë»çÀÇ Çϳª. ºÎ½ÅÇÇÁúÀÚ±Ø È£¸£¸ó
  • Addis test
    ¾Æµð½º ½ÃÇè
    12½Ã°£ µ¿¾È ¿äÀÇ ÀÏÁ¤·® Áß ÀûÇ÷±¸ ¼ö, ¹éÇ÷±¸ ¼ö, »óÇǼ¼Æ÷, ¿øÁÖ, ´Ü¹é ÇÔ·®ÀÇ ÃøÁ¤. ½ÅÀå ÁúȯÀÇ Áø´Ü°ú °ü¸®¿¡ »ç¿ëµÈ´Ù.
  • additional diagnostic test
    ºÎ°¡Àû Áø´Ü¹ý
  • Adler's test
    ¾Æµé·¯ ½ÃÇè
    µ¿ÀǾî=benzidine test. º¥ÁöµòÀÇ ºùÃÊ»ê Æ÷È­ ¿ë¾×¿¡ °°Àº ¾çÀÇ 3% °ú»êÈ­¼ö¼Ò¿Í ÇÇ°Ë¾× 1 §¢¸¦ °¡ÇÏ¿© û»öÀÌ »ý±â¸é Ç÷¾×ÀÌ Á¸ÀçÇÏ´Â °ÍÀÌ´Ù.
  • adsorption test
    ÈíÂø ½ÃÇè
  • agglutination test
    ÀÀÁý ½ÃÇè
  • agglutinin absorption test
    ÀÀÁý¼Ò Èí¼ö ½ÃÇè
    ¸é¿ª Ç÷û Áß¿¡ ÇÔÀ¯µÇ¾î ÀÖ´Â ºÒÇÊ¿äÇÑ ÀÀÁý¼Ò¸¦ Á¦¿ÜÇϰí, ƯÁ¤ÇÑ ÀÀÁý¼Ò¸¸À» ÇÔÀ¯ÇÏ´Â ÀÎÀÚ Ç÷ûÀ» ¸¸µå´Â ¹æ¹ý. ¸é¿ª Ç÷û¿¡ ÇÊ¿äÇÑ ÀÀÁý¼Ò¿¡ ´ëÇÑ ÀÀÁý¿ø
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
gene rearrangement, gamma-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the gamma-chain of antigen receptors.
(12 Dec 1998)
M antigen An antigen found in the cell of Streptococcus pyogenes; associated with virulence.
See: beta-haemolytic streptococci.
(05 Mar 2000)
receptor-CD3 complex, antigen, T-cell Molecule composed of the non-covalent association of the T-cell antigen receptor (receptors, antigen, T-cell) with the CD3 complex (antigens, CD3). This association is required for the surface expression and function of both components. The molecule consists of up to seven chains: either the alpha/beta or gamma/delta chains of the T-cell receptor, and four or five chains in the CD3 complex.
(12 Dec 1998)
receptors, antigen Molecules on the surface of b- and T-lymphocytes that recognise and combine with specific antigens.
(12 Dec 1998)
receptors, antigen, B-cell Immunoglobulin molecules on the surface of B-lymphocytes that recognise and bind antigen.
(12 Dec 1998)
receptors, antigen, T-cell Molecules on the surface of T-lymphocytes that recognise and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (antigens, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (receptors, antigen, T-cell, alpha-beta) or gamma-delta (receptors, antigen, T-cell, gamma-delta) chains.
(12 Dec 1998)
receptors, antigen, T-cell, alpha-beta T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognise antigens only when presented in association with major histocompatibility (MHC) molecules.
(12 Dec 1998)
receptors, antigen, T-cell, gamma-delta T-cell receptors composed of CD3-associated gamma and delta polypeptide chains and expressed primarily in CD4-/CD8- T-cells. The receptors appear to be preferentially located in epithelial sites and probably play a role in the recognition of bacterial antigens. The T-cell receptor gamma/delta chains are separate and not related to the gamma and delta chains which are subunits of CD3 (see antigens, CD3).
(12 Dec 1998)
receptors, very late antigen Members of the integrin family appearing late after T-cell activation. They are a family of proteins initially identified at the surface of stimulated T-cells, but now identified on a variety of cell types. At least six vla antigens have been identified as heterodimeric adhesion receptors consisting of a single common beta-subunit and different alpha-subunits.
(12 Dec 1998)
Gerbich antigen glycophorin C
Vi antigen Virulence antigen, an external capsular antigen of enterobacteria formerly thought to be related to increased virulence.
(05 Mar 2000)
partial antigen <immunology, molecular biology> Could be considered an isolated epitope: although a hapten (by definition) has an antibody directed against it, the hapten alone will not induce an immune response if injected into an animal, it must be conjugated to a carrier (usually a protein).
The hapten constitutes a single antigenic determinant, perhaps the best known example is dinitro phenol (DNP) that can be conjugated to BSA and against which antiDNP antibodies are produced (antibodies to the BSA can be adsorbed out).
Because the hapten is monovalent, immune complex formation will be blocked if the soluble hapten is present as well as the hapten carrier conjugate (assuming there is more than one hapten per carrier then an immune precipitate can be formed).
Competitive inhibition by the soluble small molecule is sometimes referred to as haptenic inhibition and this term has carried over into lectin mediated haemagglutination where monosaccharides are added to try to block haemagglutination: the blocking sugar defines the specificity of the lectin.
(18 Nov 1997)
viral antigen Those antigens specified by the viral genome (often coat proteins) that can be detected by a specific immunological response. Often of diagnostic importance.
(18 Nov 1997)
C carbohydrate antigen An antigen found in the cell wall of Streptococcus pneumoniae.
See: beta-haemolytic streptococci.
(05 Mar 2000)
CD antigen <immunology> Differentiation antigens residing on human leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similiar reactivity with certain subpopulations of antigens. The subpopulations of antigens are also known by the same CD designation.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • test ban
    ÇÙ½ÇÇè ±ÝÁö ÇùÁ¤
  • test bed
    (Ç×°ø±â ¿£Áø µîÀÇ) ½ÃÇè´ë
  • test case
    Å×½ºÆ®ÄÉÀ̽º;ù½Ãµµ;½Ã¼Ò
  • test paper
    ½ÃÇèÁö
  • test patten
    ½ÃÇè ¹æ¼Û¿ë µµÇü
  • test pilot
    (½ÅÁ¶±âÀÇ) ½ÃÇè Á¶Á¤»ç
  • test tube
    ½ÃÇè°ü
  • truefalse test
    Á¤¿À ¹®Á¦
  • tuberculin test
    Åõº£¸£Ä𸰠¹ÝÀÀ °Ë»ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á